H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on MacroGenics (MGNX) today and set a price target of $39. The company’s shares closed yesterday at $16.27.
Chattopadhyay noted:
“Our 12-month, $39 price target for shares of MacroGenics is based on a 12-year DCF-driven sum-of-the- parts analysis. Our DCF is driven by: beta of 1.8, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 11.5%, and tax rate of 15% beginning in FY 2027. (18%), flotetuzumab (16%) together represent our full target. Risks potentially incurred investing in this stock include: clinical and development, financial, regulatory and reimbursement, and commercial.”
According to TipRanks.com, Chattopadhyay is a 2-star analyst with an average return of 0.1% and a 43.1% success rate. Chattopadhyay covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Voyager Therapeutics Inc, and Autolus Therapeutics Plc.
MacroGenics has an analyst consensus of Moderate Buy, with a price target consensus of $29.25, representing a 79.8% upside. In a report issued on May 2, Cowen & Co. also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $26.39 and a one-year low of $9.87. Currently, MacroGenics has an average volume of 912K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2.
